263 related articles for article (PubMed ID: 33046486)
1. Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants.
Yoshida I; Arikawa K; Honma Y; Inatani S; Yoshinaga M; Sugiyama H
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046486
[TBL] [Abstract][Full Text] [Related]
2. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.
Choi SH; Park KS; Kim YJ
J Infect Chemother; 2019 Jul; 25(7):514-519. PubMed ID: 30885457
[TBL] [Abstract][Full Text] [Related]
3. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus entry inhibitors targeting the F protein.
Sun Z; Pan Y; Jiang S; Lu L
Viruses; 2013 Jan; 5(1):211-25. PubMed ID: 23325327
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of Cross-Resistance to Fusion Inhibitors Conferred by the K394R Mutation in Respiratory Syncytial Virus Fusion Protein.
Tang W; Li Y; Song Q; Wang Z; Li M; Zhang Q; Wang Y; Ye W; Li Y
J Virol; 2021 Sep; 95(20):e0120521. PubMed ID: 34379500
[TBL] [Abstract][Full Text] [Related]
7. Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
Brock LG; Liu X; Liang B; Lingemann M; Liu X; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925656
[TBL] [Abstract][Full Text] [Related]
8. Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
Blockus S; Sake SM; Wetzke M; Grethe C; Graalmann T; Pils M; Le Goffic R; Galloux M; Prochnow H; Rox K; Hüttel S; Rupcic Z; Wiegmann B; Dijkman R; Rameix-Welti MA; Eléouët JF; Duprex WP; Thiel V; Hansen G; Brönstrup M; Haid S; Pietschmann T
Antiviral Res; 2020 May; 177():104774. PubMed ID: 32197980
[TBL] [Abstract][Full Text] [Related]
9. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
10. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
11. Two novel fusion inhibitors of human respiratory syncytial virus.
Lundin A; Bergström T; Bendrioua L; Kann N; Adamiak B; Trybala E
Antiviral Res; 2010 Dec; 88(3):317-24. PubMed ID: 20965215
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibits respiratory syncytial virus entry and infection by blocking the interaction of the viral fusion protein with the cell membrane.
Tang W; Li M; Liu Y; Liang N; Yang Z; Zhao Y; Wu S; Lu S; Li Y; Liu F
FASEB J; 2019 Mar; 33(3):4287-4299. PubMed ID: 30571312
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein.
Yang Q; Xue B; Liu F; Lu Y; Tang J; Yan M; Wu Q; Chen R; Zhou A; Liu L; Liu J; Qu C; Wu Q; Fu M; Zhong J; Dong J; Chen S; Wang F; Zhou Y; Zheng J; Peng W; Shang J; Chen X
Signal Transduct Target Ther; 2024 Jun; 9(1):144. PubMed ID: 38853183
[TBL] [Abstract][Full Text] [Related]
14. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis.
Hotard AL; Lee S; Currier MG; Crowe JE; Sakamoto K; Newcomb DC; Peebles RS; Plemper RK; Moore ML
J Virol; 2015 Jan; 89(1):512-22. PubMed ID: 25339762
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
16. Respiratory Syncytial Virus Attachment Glycoprotein Contribution to Infection Depends on the Specific Fusion Protein.
Meng J; Hotard AL; Currier MG; Lee S; Stobart CC; Moore ML
J Virol; 2016 Jan; 90(1):245-53. PubMed ID: 26468535
[TBL] [Abstract][Full Text] [Related]
17. Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation.
Yunus AS; Jackson TP; Crisafi K; Burimski I; Kilgore NR; Zoumplis D; Allaway GP; Wild CT; Salzwedel K
Virology; 2010 Jan; 396(2):226-37. PubMed ID: 19922971
[TBL] [Abstract][Full Text] [Related]
18. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
[TBL] [Abstract][Full Text] [Related]
19. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
[TBL] [Abstract][Full Text] [Related]
20. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
